Table 2.
Univariate Cox regression for OS.
| Characteristic | HR (95% CI) | P |
|---|---|---|
| Sex (male vs. female) | 1.14 (0.73-1.78) | .575 |
| Etiology (HCV vs. HBV) | 0.71 (0.42-1.2) | .202 |
| Etiology (other vs. HBV) | 1.25 (0.51-3.06) | .621 |
| Number (>3 vs. ≤3) | 1.67 (1.21-2.31) | .002 |
| Size (>5 cm vs. ≤5 cm) | 0.9 (0.65-1.23) | .501 |
| Resection (yes vs. no) | 0.66 (0.42-1.03) | .064 |
| Ablation (yes vs. no) | 0.7 (0.52-0.95) | .023 |
| TACE (yes vs. no) | 0.4 (0.26-0.63) | 0 |
| ICI (yes vs. no) | 0.59 (0.44-0.8) | .001 |
| Lenvatinib treatment line (second vs. first) |
1.08 (0.77-1.51) | .663 |
| Lenvatinib treatment line (third vs. first) |
0.92 (0.34-2.5) | .87 |
| Metastasis (yes vs. no) | 1.75 (1.29-2.37) | 0 |
| BCLC stage (C vs. B) | 2.39 (1.54-3.72) | 0 |
| Age | 1 (0.98-1.01) | .938 |
| ECOG PS | 1.35 (1.06-1.71) | .016 |
| Child-Pugh score | 1.33 (1.18-1.49) | 0 |
| PVTT | 1.2 (1.08-1.33) | .001 |
| PNI | 0.95 (0.92-0.97) | 0 |
| log(NLR) | 2.83 (1.63-4.92) | 0 |
| log(PLR) | 3.55 (1.83-6.86) | 0 |
| log(LMR) | 0.45 (0.26-0.79) | .006 |
| log(SII) | 1.93 (1.27-2.94) | .002 |
| log(AFP) | 1.23 (1.1-1.38) | 0 |
Abbreviations: OS, overall survival; HR (95%CI), hazard ratio (95% confidence interval); HBV, hepatitis B virus; HCV, hepatitis C virus; TACE, transarterial chemoembolization; ICI, immune checkpoint inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; PVTT, portal vein tumor thrombosis; PNI, prognostic nutritional index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; SII, systemic immune-inflammatory; AFP, alpha-fetoprotein.